The Food and Drug Administration (FDA) has proposed restrictions on the use of nutritional supplements that may go into effect on October 1, 2011, unless sufficient opposition is offered. The plan is to classify supplements introduced after October, 1994, as “new dietary ingredients”, subject to expensive and prolonged testing and verification.
These restrictions would apply to resveratrol, GABA, ubiquinol, curcumin, and other products introduced in recent years, and make them no longer available to consumers, except at great expense.
Only wealthy pharmaceutical companies have the assets to undertake such testing and approval processes, which would cost in the tens of millions of dollars per item. The result would be to eliminate supplement manufacturers from competition, and raise the cost of these items astronomically. A supplement now available for $50 dollars would cost $250-$500. Some items would be financially out of reach for most people.
We have already seen this strategy in action. Patients have entered the office with bottles of omega 3 fatty acids and folic acid/B12 combinations, prescribed by physicians and obtained as pharmaceutical products, costing 5-10 times more than similar items made by reputable producers of supplements.Continue Reading
Life Extension has published 57 articles that describe the health benefits of walnuts.
Some of this same scientific data is featured on the website of Diamond Foods, Inc., a distributor of packaged walnuts.
The FDA has determined that walnuts sold by Diamond Foods cannot be legally marketed because the walnuts “are not generally recognized as safe and effective” for the medical conditions referenced on Diamond Foods’ website.
According to the FDA, these walnuts are now classified as “drugs“ and the unauthorized health claims” cause them to become “misbranded”, thus subjecting them to government “seizure or injunction“.
Let’s take a look at the science supporting the consumption of walnuts to see what the FDA is up to…and what you can do to stop it!
Click here to read the rest of this article.
The FDA plans to increase misdemeanor prosecutions of industry execs as it looks to refocus its Office of Criminal Investigations (see this letter to the Senate Finance committee). The move comes in response to a new report from the General Accountability Office that the OCI suffers from lax oversight, despite increased in funding and staffing over the past decade. In fact, the FDA hasn’t reviewed most OCI offices in more than three years. The OCI investigates counterfeit drugs and other bad stuff, as well as misconduct by FDA employees.